Tyra Biosciences (TYRA) Cash from Financing Activities (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Cash from Financing Activities data on file, last reported at $160.4 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 7233.47% year-over-year to $160.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.3 million (up 4048.07% YoY) and the FY2025 annual result came in at $8.1 million, down 95.99% from the prior year.
• Cash from Financing Activities improved to $160.4 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $200.3 million in Q1 2024 to a low of $3000.0 in Q4 2022.
• A 5-year average of $21.9 million and a median of $467000.0 in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.82% — and 2024, when it surged 53175.27%.
• Tracing TYRA's Cash from Financing Activities over 5 years: stood at $3000.0 in 2022, then jumped by 10700.0% to $324000.0 in 2023, then jumped by 117.9% to $706000.0 in 2024, then soared by 563.31% to $4.7 million in 2025, then soared by 3324.79% to $160.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $160.4 million (Q1 2026), $4.7 million (Q4 2025), and $647000.0 (Q3 2025), per Business Quant data.